(Q61656600)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

R Pujol-Borrell

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Eva Martínez-Cáceres

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Francesc E. Borràs

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Dàlia Raϊch-Regué

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Laia Grau-López

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Mar Naranjo-Gómez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

1 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

28 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

771-782

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

Immunological aspects of demyelinating diseases

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Myelin peptides in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

T cell recognition of self-antigen presenting cells by protein transfer assay reveals a high frequency of anti-myelin T cells in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Specific T-cell proliferation to myelin peptides in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Antigen-specific therapies in MS - Current concepts and novel approaches.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Tolerogenic dendritic cells for autoimmune disease and transplantation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

IL-10/TGF-beta-treated dendritic cells, pulsed with insulin, specifically reduce the response to insulin of CD4+ effector/memory T cells from type 1 diabetic individuals.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

How tolerogenic dendritic cells induce regulatory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Development of dendritic cell-based immunotherapy for autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Human dendritic cell antigen presentation and chemotaxis are inhibited by intrinsic 25-hydroxy vitamin D activation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Comparative study of clinical grade human tolerogenic dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Adherent dendritic cells expressing high levels of interleukin-10 and low levels of interleukin-12 induce antigen-specific tolerance to experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Immunomodulatory effects of Vitamin D in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Induction of tolerogenic dendritic cells by vitamin D receptor agonists

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Immunomodulatory effects of vitamin D on monocyte-derived dendritic cells in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Maturation-resistant dendritic cells induce hyporesponsiveness in alloreactive CD45RA+ and CD45RO+ T-cell populations.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Reversal of in vitro T cell clonal anergy by IL-2 stimulation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Dendritic cell therapy of high-grade gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Dendritic cell-based cancer gene therapy.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Apoptotic cell-based therapies against transplant rejection: role of recipient's dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Dendritic cells pulsed with antigen-specific apoptotic bodies prevent experimental type 1 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

A prospective study of T- and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4(+) CD25(+) CD127(low/-) FoxP3(+) T cells in patients with chronic HCV infection during pegylated interferon-alpha2a plus ribavirin treatm

1 reference

https://api.crossref.org/works/10.1002%2FEJI.201141835

7 January 2021

Identifiers

DOI

10.1002/EJI.201141835

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22488365%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference